Please assess the completion status of the following clinical trial:

Trial Title: NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~• Moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on a 4-point facial wrinkle scale) as assessed by the investigator's rating: 0 = 'none', 1 = 'mild', 2 = 'moderate', 3 = 'severe'.~Main Exclusion Criteria:~* Marked facial asymmetry.~* Ptosis of eyelid and/or eyebrow.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin®/Bocouture®) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
- OnabotulinumtoxinA (Vistabel®) (Type: ACTIVE_COMPARATOR): OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).